vs
Side-by-side financial comparison of Life360, Inc. (LIF) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($177.4M vs $146.0M, roughly 1.2× Life360, Inc.). Life360, Inc. runs the higher net margin — 88.8% vs 1.6%, a 87.2% gap on every dollar of revenue. On growth, Life360, Inc. posted the faster year-over-year revenue change (26.4% vs 5.0%). Over the past eight quarters, Life360, Inc.'s revenue compounded faster (36.6% CAGR vs -0.2%).
Life360, Inc. develops family-focused safety and connectivity platforms. Core offerings include real-time location sharing, emergency alerts, driving behavior analysis tools and identity theft protection. It serves consumer markets across North America, Europe and Asia-Pacific, with most revenue from tiered premium subscription plans.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
LIF vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $146.0M | $177.4M |
| Net Profit | $129.7M | $2.9M |
| Gross Margin | 75.1% | — |
| Operating Margin | 6.1% | 3.9% |
| Net Margin | 88.8% | 1.6% |
| Revenue YoY | 26.4% | 5.0% |
| Net Profit YoY | 1425.9% | — |
| EPS (diluted) | $1.53 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $146.0M | $196.9M | ||
| Q3 25 | $124.5M | $179.5M | ||
| Q2 25 | $115.4M | $181.1M | ||
| Q1 25 | $103.6M | $168.9M | ||
| Q4 24 | $115.5M | $187.3M | ||
| Q3 24 | $92.9M | $168.6M | ||
| Q2 24 | $84.9M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $129.7M | — | ||
| Q3 25 | $9.8M | $5.4M | ||
| Q2 25 | $7.0M | $-4.8M | ||
| Q1 25 | $4.4M | $4.8M | ||
| Q4 24 | $8.5M | — | ||
| Q3 24 | $7.7M | $-143.5M | ||
| Q2 24 | $-11.0M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | 75.1% | 79.5% | ||
| Q3 25 | 78.0% | 80.9% | ||
| Q2 25 | 78.4% | 77.4% | ||
| Q1 25 | 80.6% | 79.7% | ||
| Q4 24 | 74.0% | 78.7% | ||
| Q3 24 | 75.4% | 76.9% | ||
| Q2 24 | 75.0% | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | 6.1% | 1.2% | ||
| Q3 25 | 4.6% | 3.5% | ||
| Q2 25 | 1.7% | 4.7% | ||
| Q1 25 | 2.1% | 1.2% | ||
| Q4 24 | 4.9% | 13.2% | ||
| Q3 24 | -5.3% | -82.8% | ||
| Q2 24 | -2.8% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | 88.8% | — | ||
| Q3 25 | 7.9% | 3.0% | ||
| Q2 25 | 6.1% | -2.7% | ||
| Q1 25 | 4.2% | 2.8% | ||
| Q4 24 | 7.4% | — | ||
| Q3 24 | 8.3% | -85.1% | ||
| Q2 24 | -12.9% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $1.53 | $0.05 | ||
| Q3 25 | $0.11 | $0.12 | ||
| Q2 25 | $0.08 | $-0.11 | ||
| Q1 25 | $0.05 | $0.10 | ||
| Q4 24 | $0.14 | $0.38 | ||
| Q3 24 | $0.09 | $-3.11 | ||
| Q2 24 | $-0.15 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $494.3M | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $548.2M | $653.9M |
| Total Assets | $959.7M | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $494.3M | $238.4M | ||
| Q3 25 | $455.7M | $246.3M | ||
| Q2 25 | $432.7M | $445.9M | ||
| Q1 25 | $168.9M | $493.6M | ||
| Q4 24 | $159.2M | $484.6M | ||
| Q3 24 | $159.0M | $453.8M | ||
| Q2 24 | $160.8M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $548.2M | $693.1M | ||
| Q3 25 | $391.4M | $727.2M | ||
| Q2 25 | $366.7M | $757.8M | ||
| Q1 25 | $376.3M | $798.5M | ||
| Q4 24 | $358.5M | $778.3M | ||
| Q3 24 | $339.7M | $749.6M | ||
| Q2 24 | $326.7M | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $959.7M | $1.3B | ||
| Q3 25 | $787.5M | $1.3B | ||
| Q2 25 | $753.6M | $1.5B | ||
| Q1 25 | $455.4M | $1.6B | ||
| Q4 24 | $441.6M | $1.6B | ||
| Q3 24 | $427.4M | $1.5B | ||
| Q2 24 | $405.9M | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $36.8M | — |
| Free Cash FlowOCF − Capex | $36.6M | — |
| FCF MarginFCF / Revenue | 25.1% | — |
| Capex IntensityCapex / Revenue | 0.2% | — |
| Cash ConversionOCF / Net Profit | 0.28× | — |
| TTM Free Cash FlowTrailing 4 quarters | $86.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $36.8M | $43.7M | ||
| Q3 25 | $26.4M | $60.8M | ||
| Q2 25 | $13.3M | $12.0M | ||
| Q1 25 | $12.1M | $35.5M | ||
| Q4 24 | $12.3M | $33.1M | ||
| Q3 24 | $6.3M | $53.9M | ||
| Q2 24 | $3.3M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $36.6M | $43.5M | ||
| Q3 25 | $25.6M | $57.0M | ||
| Q2 25 | $12.7M | $9.3M | ||
| Q1 25 | $11.9M | $26.9M | ||
| Q4 24 | $11.2M | $31.0M | ||
| Q3 24 | $6.3M | $49.8M | ||
| Q2 24 | $3.2M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | 25.1% | 22.1% | ||
| Q3 25 | 20.6% | 31.7% | ||
| Q2 25 | 11.0% | 5.1% | ||
| Q1 25 | 11.5% | 15.9% | ||
| Q4 24 | 9.7% | 16.6% | ||
| Q3 24 | 6.8% | 29.6% | ||
| Q2 24 | 3.8% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 0.2% | 0.1% | ||
| Q3 25 | 0.6% | 2.2% | ||
| Q2 25 | 0.6% | 1.5% | ||
| Q1 25 | 0.1% | 5.1% | ||
| Q4 24 | 1.0% | 1.1% | ||
| Q3 24 | 0.0% | 2.4% | ||
| Q2 24 | 0.1% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | 0.28× | — | ||
| Q3 25 | 2.70× | 11.20× | ||
| Q2 25 | 1.90× | — | ||
| Q1 25 | 2.75× | 7.37× | ||
| Q4 24 | 1.45× | — | ||
| Q3 24 | 0.83× | — | ||
| Q2 24 | — | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LIF
Segment breakdown not available.
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
